BR112014005793A2 - compostos inibidores de enzimas - Google Patents

compostos inibidores de enzimas

Info

Publication number
BR112014005793A2
BR112014005793A2 BR112014005793A BR112014005793A BR112014005793A2 BR 112014005793 A2 BR112014005793 A2 BR 112014005793A2 BR 112014005793 A BR112014005793 A BR 112014005793A BR 112014005793 A BR112014005793 A BR 112014005793A BR 112014005793 A2 BR112014005793 A2 BR 112014005793A2
Authority
BR
Brazil
Prior art keywords
pyridin
chlorophenyl
pyrazolo
pyrrolo
piperidin
Prior art date
Application number
BR112014005793A
Other languages
English (en)
Inventor
Stewart Alison
Carley Allison
Evans David
Savory Edward
Nordling Erik
Simpson Iain
Nilsson Marianne
Haraldsson Martin
Higginbottom Michael
Koolmeister Tobias
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of BR112014005793A2 publication Critical patent/BR112014005793A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

resumo patente de invenção: "compostos inibidores de enzimas". 2-{4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidin-1-il}etan-1-amina; 4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidina-1-carboxilato de 3-aminopropila; 1-{4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidin-1-il}-4-(dimetilamino)butan-1-ona; 5-amino-1-{4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidin-1-il}pentan-1-ona; n-(2-aminoetil)-4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidina-1-carboxamida; n-(3-aminopropil)-4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidina-1-carboxamida; 4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]-n-[3-(dimetilamino)propil]piperidina-1-carboxamida; 1-({4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidin-1-il}carbonil)piperazina; 4-({4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidin-1-il}carbonil)morfolina; 1-({4-[1-(4-clorofenil)-1h-pirrolo[2,3-c]piridin-3-il]piperidin-1-il}carbonil)-1,4-diazepano; 1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidina-4-carboxilato de etila; 1-[1-(4-metilfenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidina-4-carboxilato de etila; ácido 1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidina-4-carboxílico; n-(2-aminoetil)-1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidina-4-carboxamida; 4-({1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidin-4-il}carbonil)morfolina; 1-({1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidin-4-il}carbonil)piperazina; {4-[1-(4-metilfenil)-1h-pirazolo[3,4-c]piridin-3-il]morfolin-3-il}metanol; {4-[1-(4-metilfenil)-1h-pirazolo[3,4-c]piridin-3-il]morfolin-2-il}metanol; [(3r)-4-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]morfolin-3-il]metanol; 4-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]morfolina-3-carboxilato de metila; n-(2-aminoetil)-4-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]morfolina-3-carboxamida; 2-{4-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]morfolin-3-il}etan-1-ol; 1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidina-2-carboxilato de metila; n-(2-aminoetil)-1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidina-2-carboxamida; 1-({1-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidin-2-il}carbonil)piperazina; 4-[1-(4-metilfenil)-1h-pirrolo[2,3-c]piridin-3-il]morfolina; 1-(4-clorofenil)-3-(piperidin-4-il)-1h-pirrolo[2,3-c]piridin-4-ol; n-butil-1-(4-clorofenil)-n-metil-1h-pirazolo[3,4-c]piridin-3-amina; 1-[4-(fluorometil)fenil]-3-(oxan-4-il)-1h-pirazolo[3,4-c]piridina; e 3-({4-[1-(4-clorofenil)-1h-pirazolo[3,4-c]piridin-3-il]piperidin-1-il}metil)piridina são utilizáveis para a inibição da atividade de ssao.
BR112014005793A 2011-09-14 2011-09-14 compostos inibidores de enzimas BR112014005793A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/065967 WO2013037411A1 (en) 2011-09-14 2011-09-14 New enzyme inhibitor compounds

Publications (1)

Publication Number Publication Date
BR112014005793A2 true BR112014005793A2 (pt) 2017-03-28

Family

ID=44677871

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005793A BR112014005793A2 (pt) 2011-09-14 2011-09-14 compostos inibidores de enzimas

Country Status (12)

Country Link
US (1) US9150574B2 (pt)
EP (1) EP2755974A1 (pt)
JP (1) JP5796130B2 (pt)
CN (1) CN103889983B (pt)
AU (1) AU2011376717A1 (pt)
BR (1) BR112014005793A2 (pt)
CA (1) CA2847193A1 (pt)
EA (1) EA201490451A1 (pt)
IL (1) IL231353A0 (pt)
IN (1) IN2014DN01883A (pt)
SG (1) SG11201400277VA (pt)
WO (1) WO2013037411A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201416446D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
GB201507031D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd New pharmaceutical salt forms
CA3007768A1 (en) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
WO2018129557A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
JP2021535159A (ja) * 2018-08-27 2021-12-16 スピノジェニックス， インコーポレイテッド スパイン形成のためのファシン結合化合物
WO2020239855A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
EP4136076A1 (en) * 2020-04-16 2023-02-22 F. Hoffmann-La Roche AG Biphenyl derivatives
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2023193790A1 (en) * 2022-04-08 2023-10-12 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
EP1216244B1 (en) 1999-09-14 2003-08-13 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
AU2002341920A1 (en) * 2001-10-02 2003-04-14 Smithkline Beecham Corporation Chemical compounds
US7456169B2 (en) 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
JP2007501802A (ja) 2003-08-08 2007-02-01 ラ ホヤ ファーマシューティカル カンパニー 疾患の処置に有用な、セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）およびｖａｐ−１媒介性接着のインヒビター
KR101151653B1 (ko) 2003-09-17 2012-06-28 얀센 파마슈티카 엔.브이. 융합된 헤테로사이클릭 화합물
US20060025383A1 (en) 2004-02-03 2006-02-02 Neil Wishart Aminobenzoxazoles as therapeutic agents
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US8859581B2 (en) 2005-04-25 2014-10-14 Merck Patent Gmbh Azaheterocyclic compounds as kinase inhibitors
DK1906965T3 (en) 2005-06-22 2015-08-03 Chemocentryx Inc Azaindazol compounds and methods of use thereof
WO2007120528A2 (en) 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
MX2008012734A (es) 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
US20100099673A1 (en) 2007-01-17 2010-04-22 Bilodeau Mark T Decahydroquinoline analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
JP2010525032A (ja) 2007-05-02 2010-07-22 ノバルティス アーゲー ヘテロ環化合物及び殺有害生物剤としてのそれらの使用
GB0725103D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
BRPI0906727A2 (pt) 2008-01-31 2015-08-04 Sanofi Aventis Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
CA2737527C (en) 2008-09-16 2015-12-29 Proximagen Limited 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds useful as inhibitors of ssao activity
EP2328895B1 (en) * 2008-09-16 2013-03-27 Proximagen Limited Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO
JP2012510983A (ja) 2008-12-04 2012-05-17 プロキシマジェン エルティーディー イミダゾピリジン化合物
JP2012211085A (ja) 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds

Also Published As

Publication number Publication date
JP2015502913A (ja) 2015-01-29
US20140357623A1 (en) 2014-12-04
CA2847193A1 (en) 2013-03-21
US9150574B2 (en) 2015-10-06
EA201490451A1 (ru) 2014-12-30
EP2755974A1 (en) 2014-07-23
JP5796130B2 (ja) 2015-10-21
CN103889983A (zh) 2014-06-25
IL231353A0 (en) 2014-04-30
WO2013037411A1 (en) 2013-03-21
AU2011376717A1 (en) 2014-03-20
IN2014DN01883A (pt) 2015-05-15
SG11201400277VA (en) 2014-05-29
CN103889983B (zh) 2015-12-09

Similar Documents

Publication Publication Date Title
BR112014005793A2 (pt) compostos inibidores de enzimas
NZ602141A (en) Inhibitors of semicarabazide-sensitive amine oxidase
RU2018115722A (ru) N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
TR201904785T4 (tr) (S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
MX2008008405A (es) Metodos para tratar lupus cutaneo usando compuestos de aminoisoindolina.
WO2014028445A3 (en) Cereblon isoforms and their use as biomarkers for therapeutic treatment
CL2014000534A1 (es) Procesos para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo y compuestos intermediarios, inhibidores de jak; y compuesto intermediario (3-fluoro-2-(trifluorometil)piridin-4-il)(1,4-dioxa-8-azaspiro[4,5]decan-8-il)metanona.
NZ630488A (en) Piperidine derivatives for gpr119 agonist
TR201903901T4 (tr) Lizosomal depolama bozukluklarının önlenmesi ve/veya tedavisi için yeni kompozisyonlar.
PH12013500773A1 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
WO2007041637A3 (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
AR079198A1 (es) Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
NZ592792A (en) Heterocyclically substituted aryl compounds as hif inhibitors
NZ592508A (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
IL196885A (en) Use of 3- (4-amino-1-oxo-3,1-dihydro-isoindole-2-ram) -pipridine-6,2-discussion for preparation of a drug for the treatment of mental cell lymphomas
NZ594765A (en) Anthelmintic agents and their use
WO2010052448A3 (en) Fused pyrazine derivatives as kinase inhibitors
PE20141370A1 (es) Inhibidores de quinasa
NZ620635A (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
AU2011305525A8 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
AR044821A1 (es) 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4
NO20084674L (no) 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
JP2018503695A5 (pt)
HK1195066A1 (zh) -{ }- -{ -三氟乙氧基 -苯並異噁唑- -基 氧}甲基 哌啶- -基 甲基}-四氫- -吡喃- -羧酸的多晶型形式
RU2013102399A (ru) Производные (3-метилпирролидин-3-ил)-метил пиридинилового эфира и их применение в качестве антагонистов рецептора nk-3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]